Under the agreement, Celularity will provide Arthrex exclusive rights to distribute its placental-derived regenerative orthopedic products.
“Partnering with Celularity positions us to explore new opportunities in the orthobiologics space while continuing our mission of helping surgeons better treat their patients,” Arthrex senior director of orthobiologics, David Shepard, said.
